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Objective: Advanced/metastatic or recurrent endometrial cancer has a poor prognosis.
Malignant endometrial tissue has high steroid sulphatase (STS) activity. The aim of this
study was to evaluate STS as a therapeutic target in patients with endometrial cancer.
Methods: This was a phase 2, multicenter, international, open-label, randomized (1:1), 2-
arm study of the STS inhibitor oral irosustat 40 mg/d versus oral megestrol acetate 160 mg/d
in women with advanced/metastatic or recurrent estrogen receptorYpositive endometrial
cancer. The primary end point was the proportion of patients without progression or death
6 months after start of treatment. Secondary end points included progression-free survival,
time to progression, overall survival, and safety.
Results: Seventy-one patients were treated (36 with irosustat, 35 with megestrol acetate).
The study was prematurely stopped after futility analysis. Overall, 36.1% and 54.1% of
patients receiving irosustat or megestrol acetate had not progressed or died at 6 months,
respectively. There were no statistically significant differences between irosustat and
megestrol acetate in response and overall survival rates. Irosustat patients had a median
progression-free survival of 16 weeks (90% confidence interval, 9.0Y31.4) versus 40 weeks
(90% confidence interval, 16.3Y64.0) in megestrol acetate patients. Treatment-related ad-
verse events occurred in 20 (55.6%) and 13 (37.1%) patients receiving irosustat or
megestrol, respectively. Most adverse events in both groups were grade 1 or 2.
Conclusions: Although irosustat monotherapy did not attain a level of activity sufficient
for further development in patients with advanced/recurrent endometrial cancer, this study
confirms the activity of hormonal treatment (megestrol acetate) for this indication.
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Despite progress in the therapy of early endometrial cancer,advanced or recurrent endometrial cancer has a poor
prognosis. The treatment of advanced metastatic endometrial
cancer relies on systemic therapy.1 The activity of cytotoxic
drugs in advanced disease is limited (up to 40% response rate
in chemotherapy-naBve patients2), and the administration of
cytotoxic drugs is accompanied by high toxicity1 in this older
population who are likely to have comorbidities.
Estrogens play a central role in the development of
endometrial cancer.3,4 The overproduction of estradiol (E2),
estrone (E1), and testosterone in endometrial tissue is asso-
ciated with the development of endometrial cancer.5Y7
Hormonal therapy for recurrent endometrial cancer
relies on the expression of hormone receptors, which act as
nuclear transcription factors. For example, the expression of
estrogen receptor (ER)-> in metastatic endometrial carcinoma
tissue is statistically significantly related to clinical response
to medroxyprogesterone acetate,8 the hormonal agent used
most commonly in patients with advanced/metastatic endo-
metrial cancer. Another common hormonal therapy used is
the antiprogesterone agent, megestrol acetate, which, when
administered as monotherapy, results in a response rate of
15% to 30% in this setting.9,10
Tamoxifen, aromatase inhibitors, and luteinising
hormoneYreleasing hormone agonists have also been used to
treat endometrial cancer.11Y14 However, these agents have only
a limited activity in advanced/metastatic endometrial cancer
(9% to 33% response rate15). Nevertheless, in a recently pub-
lished study of exemestane, 35% of patients with ER-positive
disease had not progressed after 6 months.16 Another study
combining letrozolewith everolimus reported clinical benefit in
40% of 35 enrolled patients with recurrent endometrial can-
cer.17 Collectively, evidence suggests that a new generation of
agents suitable for use in combination therapy and with higher
specificity and fewer adverse effects is required, possibly
targeting different mechanisms of action.
Steroid sulphatase (STS) is an enzyme that plays a
pivotal role in the formation of E2 and androstenediol.6,18
Malignant endometrial tissue possesses significantly higher
STS activity and STS mRNA expression compared with
normal endometrium,19,20 providing a rationale for targeting
the STS enzyme to treat endometrial cancer. Irosustat, a po-
tent inhibitor of STS, has been shown to inhibit endometrial
cancer growth in nude mice and has demonstrated activity in
phase 1 clinical studies of patients with hormone-dependent
breast cancer in whom the agent was well tolerated.6,21Y23
The high in vitro specificity against STS and safety and
tolerability in clinical studies of breast cancer6,21Y23 served as
a basis for evaluation of irosustat in endometrial cancer. This
study aimed to determine the antitumor efficacy, tolerability,
and safety of irosustat compared with megestrol acetate in
women with advanced/metastatic or recurrent ER-positive
endometrial cancer.
MATERIALS AND METHODS
The study was conducted in 34 centers in 12 countries
(Belgium,CzechRepublic, France,Hungary, Latvia,Lithuania,
Poland, Republic of Moldova, Russian Federation, Spain,
Ukraine, andUnitedKingdom)betweenNovember2009andJuly
2013 (ClinicalTrials.gov clinical trial number: NCT00910091).
Seventy-three of the planned 80 patients were ran-
domized. On June 6, 2011, the results of a futility analysis
indicated that the probability of demonstrating superiority of
irosustat over megestrol acetate in terms of progression-free
survival (PFS) was very low. Consequently, the study spon-
sor decided to discontinue enrolment into the study. Patients
already enrolled were informed of the decision and were of-
fered the option to continue receiving the study treatment.
They were also informed of the potential impact if they
wished to remain in the study.
The trial was conducted according to the Declaration of
Helsinki and International Harmonisation of Good Clinical
Practice. All applicable local independent ethical committee
and institutional review board approvals were obtained before
starting the trial. All patients gave written informed consent.
Patients
Postmenopausal women with histologically confirmed,
advanced, or recurrent endometrial carcinoma not eligible for
treatment with surgery or radiotherapy alone; documented ER
positivity (defined by at least 10% of positive cells in the
primary tumor or in the metastatic tissue, if the primary tumor
is unavailable); at least 1 measurable disease lesion, according
to the Response Evaluation Criteria in Solid Tumours
(RECIST) version 1.0; minimum indicator lesion size 20 mm
(conventional techniques) or 10 mm (spiral computed to-
mography scan); target lesions not situated in the irradiated
area; no history of other malignant disease except treated
basal cell or high-grade cervical intraepithelial neoplasia in
the previous 5 years; life expectancy of 6 months or more; and
Eastern Cooperative Oncology Group performance status of 2
or less were enrolled in the present study.
Key exclusion criteria included previous systemic treat-
ment for endometrial cancer with the exception of adjuvant
chemotherapy; known central nervous system metastases; on-
going cardiac dysrhythmias or atrial fibrillation; concomitant
use of carbonic anhydrase-II inhibitors; contraindications to
megestrol acetate including hypersensitivity to one of the
components of the drug product; any active arterial or venous
thromboembolic event, or uncontrolled hypertension; and ab-
normal baseline findings that might jeopardize patient safety.
Study Design
This was a phase 2, multicenter, international, open-
label, randomized, 2-arm study of oral irosustat 40 mg/d
(ie, the dose that was previously established in a phase 1, dose-
escalation study21) versus oral megestrol acetate 160 mg/d.
Participants were randomized 1:1 to receive either treatment
until objective tumor progression, 2 years after the last patient
was randomized (June 3, 2011), withdrawal, or death. A
computer-generated master randomization list generated in
blocks according to a balance ratio was prepared and managed
by a statistician independent from the study. The randomization
number and associated treatmentwas allocated by an interactive
voice/web response system service that was available to study
investigators around the clock. Both drugs were taken once a
day in themorning and under fasting conditions. Crossover into
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the other arm on progression on 1 treatment was not predefined
within the study design.
The primary end point was the proportion of patients
who had neither progressed nor died 6months after the start of
treatment. Secondary end points included PFS (time from
randomization until objective tumor progression or death
from any cause), clinical benefit (defined as complete re-
sponse [CR] + partial response [PR] + stable disease [SD] Q12
weeks; as measured using RECIST version 1.0), the overall
response (defined as CR + PR), the time to progression, the
duration of response, the overall survival (OS) after 2 years,
and the safety and tolerability of irosustat. Disease control
(defined as PR + SD) formed a post hoc end point of the study.
Assessments
Tumor response was evaluated using computed to-
mography or magnetic resonance imaging, and RECIST
version 1.024 at baseline and every 8 weeks with a subsequent
radiological central review. The intensity of staining was not
taken into account V only the proportion of stained cells;
there was no central review of slides. The study centers
provided survival status every 6 months until the end of the
study (2 years after the randomization of the last patient).
Adverse events (AEs) were monitored from the time of study
entry to the end of the study. AEswere graded according to the
National Cancer Institute Common Terminology Criteria for
Adverse Events.25
Statistical Analysis
The primary population for the analyses was the
intention-to-treat (ITT) population (all randomized patients),
although sensitivity analyses of the primary end point and
PFS were performed in the modified ITT (mITT) population
(all randomized patients who received at least 1 treatment
dose and had at least 1 measurable lesion according to
RECIST criteria at baseline). The proportion of patients who
had neither progressed nor died 6 months after the start of
treatment was expected to be 50% in the irosustat arm and
25% in the megestrol acetate arm.10,26 Using a 1-stage
Fleming design27 and assuming a 1-sided alpha of 0.05, the
study was planned to have 91% power to reject the null hy-
pothesis with a sample size of 32 evaluable patients per group.
Assuming awithdrawal rate of 20%, the aimwas to randomize
40 patients to each treatment arm to ensure 32 evaluable
patients per arm, for a total sample size of 80.
Descriptive statistical analyses were carried out on the
ITT population and percentage changes frombaselinewere also
calculated. All statistical analyses were performed as 2-sided
tests with a type 1 error rate set at 10%. The primary end
point was calculated for each treatment group using normal
binomial distribution together with 90% confidence intervals
(CI). Secondary end point time event data were analyzed using
Cox proportional hazards model and Kaplan-Meier plots.
RESULTS
Patients
Patient disposition is shown in Figure 1; 73 of the
planned 80 patients were randomized before the study was
terminated (36 in the irosustat arm and 37 in the megestrol
acetate arm; ITTpopulation), and 71patientswere treated (36 in
the irosustat group and 35 in themegestrol acetate group; safety
population; mITT population consisted of 35 in the irosustat
arm and 34 in the megestrol acetate arm). Thus, the number of
patients needed for statistical analyses was achieved.
Baseline characteristics and disease history were well
balanced between treatment arms (Table 1). All patients en-
rolled in the study had ER-positive endometrial cancer and
therefore were deemed to have type 1 or 2 endometrial cancer.
Efficacy
Overall, 36.1% (90% CI, 24.3Y49.8) of patients re-
ceiving irosustat had not progressed or died at 6 months
compared with 54.1% (90% CI, 40.8Y66.8; P = NS) of pa-
tients in the megestrol acetate arm (Table 2). The median PFS
was 16.1 weeks (90% CI, 9.0Y31.4) versus 40.1 weeks (90%
CI, 16.3Y64.0; P = NS) for patients receiving irosustat and
megestrol acetate, respectively (Fig. 2a). The median time to
progression in the ITT population was 16.3 weeks (90% CI,
9.0Y31.4) versus 40.1 weeks (90% CI, 24.1Y64.0; P = 0.04)
for patients receiving irosustat and megestrol acetate, re-
spectively. The median duration of response was 105.1 weeks
in the megestrol acetate arm, but was not calculable in the
irosustat arm. Clinical benefit was achieved in 57.1% of
irosustat-treated patients and 70.6% of megestrol acetate-
treated patients (Table 2). The overall response rate (35.3%
and 8.6%) and disease control rate (64.7% and 57.1%) were
higher in the megestrol acetate arm compared with the irosustat
arm (Table 2). Median OS was not reached in the megestrol
acetate arm and was 63.4 weeks in the irosustat arm (Fig. 2b).
Adverse Events
Patients were exposed to irosustat and megestrol acetate for
a median of 16.2 (range, 2.0Y136.1) and 40.0 (range, 2.3Y160.0)
weeks, respectively.
Overall, 179 treatment-emergent AEs (TEAEs) were
observed in 32 (88.9%) patients in the irosustat arm, and 186
TEAEs were observed in 29 (82.9%) patients in the megestrol
acetate arm. Most TEAEs were grade 1 or 2 (mild to mod-
erate; 154/179 [86%] with irosustat and 169/186 [91%] with
megestrol acetate; 18 [10.1%], 2 [1.1%], and 1 [0.6%] grade
3, 4, and 5 TEAEs, respectively, in the irosustat arm and 16
[8.6%], 0 [0%], and 1 [0.5%] grade 3, 4, and 5 TEAEs, re-
spectively, in the megestrol acetate arm). Treatment-related
AEs (TRAEs) occurred in 20 (55.6%) patients in the
irosustat arm and 13 (37.1%) patients in the megestrol acetate
arm (Table 3). The most frequent TRAE in both study arms
was dry skin. Grade 3 or higher TRAEs in the irosustat arm
included dry skin, asthenia, hyponatremia, and hypertension
(all n = 1), and grade 3 or higher TRAEs in the megestrol
acetate arm included pulmonary embolism (n = 2) and hy-
perglycemia (n = 1; Table 3).
Study drug was permanently discontinued in 4 patients
because of 5 TEAEs (3 patients in the irosustat arm, including
1 patient with grade 3 acute myocardial infarction considered
not related to study drug, 1 patient with grade 3 hyponatremia
considered related to study drug, and 1 patient with a grade 2
tumor hemorrhage considered not related to study drug as
International Journal of Gynecological Cancer & Volume 00, Number 00, Month 2016 Irosustat Versus Megestrol Acetate
* 2016 IGCS and ESGO 3
Copyright © 2016 by IGCS and ESGO. Unauthorized reproduction of this article is prohibited.
well as 1 patient with grade 3 dyspnea and grade 3 pleural
effusion considered not related to study drug in the megestrol
acetate arm).
Serious AEs (SAEs) were reported in 9 patients in the
irosustat arm and 6 patients in the megestrol acetate arm.
Among the SAEs, there were 2 deaths reported during the
studyV 1 patient in the irosustat group with lower respiratory
tract infection and lung metastases from endometrial cancer,
assessed as not related to study drug, and 1 patient in the
megestrol acetate group with a pulmonary embolism assessed
as related to study drug. The SAEs in the irosustat arm, each
occurring in a different patient, included grade 3 inadequate
control of diabetes; grade 3 acute renal failure; grade 3
vomiting and grade 2 asthenia; grade 2 hematuria; grade 2
anemia; grade 3 upper abdominal pain; grade 4 anemia; grade
2 nephrolithiasis; and grade 2 renal colic. None of these SAEs
were considered related to study drug, but 1 patient had grade
3 asthenia, grade 3 hyponatremia, grade 2 decreased appetite,
and grade 2 constipation, which were all considered related to
study drug. The SAEs in the megestrol acetate arm, each
occurring in a different patient, included grade 3 urinary re-
tention; grade 3 dyspnea and grade 3 pleural effusion; grade 2
urinary retention; grade 3 vomiting; and grade 3 myocardial
infarction. None of these SAEs were considered related to
study drug, but 1 patient had a grade 3 pulmonary embolism
considered related to study drug and 1 patient had a grade 4
pulmonary embolism leading to death that was considered
related to study drug.
Aclinically significant grade4hematological abnormality
(anemia) judged unrelated to treatment and a nonclinically sig-
nificant grade 4 abnormal potassium value were reported in 1
patient each in the irosustat group. Four patients in the irosustat
group and 4 patients in the megestrol acetate group experienced
grade 4 hematological values. Among these patients, decreased
lymphocyte counts in 2 patients (1 in each treatment group)were
judged by the investigator as clinically significant. In addition, 3
of 10 grade 4 biochemistry values in irosustat-treated patients
and 6 of 13 in the megestrol acetate groupwere considered to be
clinically significant.
DISCUSSION
In this randomized phase 2 trial, the investigational
hormonal agent irosustat, evaluated as a single agent in patients
with advanced/metastatic or recurrent endometrial cancer,
failed to demonstrate the preplanned efficacy (the proportion of
patients who had neither progressed or died after 6 months of
treatment) compared with the reference hormonal treatment
(megestrol acetate) because only one third of patients did not
progress or die after 6months. Thedisease control rate (PR+SD)
FIGURE 1. Patient flow/disposition.
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of 55.6% in the irosustat arm was also numerically inferior
compared with the disease control rate of 59.4% with
megestrol acetate.
Nevertheless, these results demonstrate long-term dis-
ease control with hormonal therapy in a subgroup of patients.
More than 50% of patients were alive and 31% progression-
free 2 years after the start of treatment with megestrol acetate.
This response rate is higher than previously reported in other
studies for patients with advanced/metastatic endometrial
cancer treated with megestrol acetate,9,10 indicating that
hormone therapy remains a treatment option in this patient
population with ER-positive tumors.
Most of the hormonal therapy studies in metastatic
endometrial carcinoma were conducted more than a decade
ago in a nonselected population of patients (in relation to ER
expression), and the therapeutic approach in this setting has
evolved since that time. Taxane-platinYbased combination
chemotherapy has become established, and supportive care of
the comorbid conditions has improved. The present pro-
spective trial confirms the activity of megestrol acetate in the
current era characterized by the advent of targeted therapy and
wide use of taxanes and platinum. A 3-year survival rate of
more than 50% of patients with long-term disease control
suggests that megestrol acetate may be considered for the
treatment of systemic treatment-naive patients with metastatic
ER-positive endometrial cancer.9,28Y30
Many endometrial carcinomas express estrogen and
progesterone receptors, and positivity for these receptors is
associated with better treatment outcome.5,6 Receptor-
positive tumors also tend to be more differentiated (lower
grades) than those without hormone receptors,6 and it has
been suggested that receptor-positive, well-differentiated tu-
mors reflect the subset of responding tumors in hormonal
therapy trials. In this study, such subsets of responsive tumors
may have existed and contributed to the observed findings.
For example, although all patients enrolled had ER-positive
tumors, there were between-group differences in the propor-
tion of tumors that tested positive for progesterone receptor. It
TABLE 1. Patient and disease characteristics at baseline
(ITT population)
Irosustat
(N = 36) n (%)
Megestrol Acetate
(N = 37) n (%)
Age, mean (SD), y 68.1 (11.4) 67.4 (8.6)
BMI, kg/m2 V V
G18.5 1 (2.8) 0
18.5Y25 10 (27.8) 10 (27.0)
925Y30 10 (27.8) 8 (21.6)
930 12 (33.3) 17 (45.9)
Missing 3 (8.3) 2 (5.4)
Time since diagnosis,
median (range), y




Yes 24 (66.7) 22 (59.5)
No 12 (33.3) 15 (40.5)
Prior surgery
Yes 30 (83.3) 29 (78.4)




0 13 (36.1) 15 (40.5)
1 19 (52.8) 16 (43.2)
2 4 (11.1) 4 (10.8)




I 13 (36.1) 10 (27.0)
II 7 (19.4) 7 (18.9)
III 9 (25.0) 12 (32.4)
IV 7 (19.4) 8 (21.6)
Histological type V V
Endometrioid 22 (61.1) 24 (64.9)
Endometrial 10 (27.8) 12 (32.4)
Uterine papillary 2 (5.6) 1 (2.7)
Mucinous 1 (2.8) 0
Mixed 1 (2.8) 0
Histological grade V V
G1 8 (22.2) 10 (27.0)
G2 17 (47.2) 18 (48.6)
G3 9 (25.0) 8 (21.6)
Missing 2 (5.6) 1 (2.7)
No. metastatic disease V V
1 7 (19.4) 16 (44.4)
2Y3 22 (61.1) 13 (36.1)
93 4 (11.1) 5 (13.9)
ER status V V
Positive 36 (100) 37 (100)
TABLE 1. (Continued)
Irosustat
(N = 36) n (%)
Megestrol Acetate






Positive 25 (69.4) 32 (86.5)
Negative 9 (25.0) 4 (10.8)
Unknown 0 0
Missing 2 (5.6) 1 (2.7)
Values are n (%) unless otherwise stated.
BMI indicates body mass index; ECOG, Eastern Cooperative
Oncology Group; FIGO, International Federation of Gynecology and
Obstetrics; and SD, standard deviation.
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is possible that the higher proportion of progesterone
receptorYpositive tumors, at baseline, in patients treated with
megestrol acetate, when compared with irosustat, may have
influenced the higher than expected response to megestrol
acetate. Moreover, most tumors in both treatment groups were
of grade 1 or 2 histology. Response was not evaluated by
histology grade, but evidence from existing treatments sug-
gests that grade 1 or 2 tumors may be more responsive to
treatment than higher grade tumors.
A large study ofmedroxyprogesterone acetate showed the
overall response rate was higher in grade 1 and 2 tumors com-
paredwith grade 3 tumors.26 Other hormonal monotherapies for
endometrial cancer include the luteinising hormone-releasing
hormone agonist triptorelin. The overall response rate to
triptorelin in the phase 2 multicenter study in 24 patients with
advanced or recurrent endometrial cancer was low (1 patient
with a CR, 1 patient with a PR, and 5 patients with SD).31 The
aromatase inhibitors letrozole and anastrozole have also been
evaluated but were found to have very little activity against
endometrial cancer, although the studies included patients with
grade 2 or 3 tumors, which are less sensitive to hormonal
treatment.12,32 Tamoxifen has also been studied as first-line
therapy for patients with recurrent or metastatic endometrial
cancer.14 A Gynecologic Oncology Group study in 68 patients
with unselected advanced/recurrent endometrial cancer reported
a response rate of only 10% (3 patients with a CR and 4 patients
with a PR)with amedian PFS of 1.9months and amedianOSof
8.8 months.14 However, a higher overall response rate to ta-
moxifen was observed among patients with grade 1 or 2 his-
tology compared with grade 3 histology (response rates were
24% for grade 1, 14% for grade 2, and 3% for grade 3). These
FIGURE 2. Kaplan-Meier plot of (A) PFS (mITT population) and (B) OS (ITT population) for patients receiving irosustat
(solid line) and megestrol acetate (dashed line).
TABLE 2. Response to treatment with irosustat or
megestrol acetate (ITT population)
Irosustat




Patients who have not
progressed or died at
6 m, % (90% CI)
36.1 (24.3Y49.8) 54.1 (40.8Y66.8)
Response* V V
Complete response 0 2 (5.4)
Partial response 3 (8.3) 10 (27.0)
SD Q12 w 17 (47.2) 12 (32.4)
Progressive disease 14 (38.9) 8 (21.6)
Not evaluable 1 (2.8) 2 (5.4)
Values are n (%) unless otherwise stated.
*mITT population.
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results suggest that ER/PR expression and not subjective as-
sessment of tumor differentiation should be the principal se-
lection criterion for hormone therapy.
Studies of hormone or combination chemotherapy
regimens have reported median OS in the range of 7.0 to
38 months in patients with advanced or recurrent endometrial
cancer.14,15,33,34 The median OS, although not reached in the
megestrol acetate arm, was 63.4 weeks (15 months) in the
irosustat arm of the current study. This finding is within the
range seen with existing treatments in the advanced/recurrent
population, and is similar to survival (medianOSof 13.3months)
recently achievedwith the aromatase inhibitor, exemestane, in a
patient population broadly similar to that enrolled in the current
study (ie, ER-positive patients with advanced or recurrent en-
dometrial cancer).17
There are also marked and clinically significant dif-
ferences in the adverse-effect profiles of hormonal treatments
compared with chemotherapy in the advanced/recurrent set-
ting. Although, in the current study, 1 patient in the megestrol
acetate group died from pulmonary embolism assessed as
related to study drug, most other life-threatening toxicities of
a combination regimen of cytotoxic drugs are not generally
encountered in patients treated with hormonal agents. In the
current study, the overall frequency of AEs was higher with
irosustat than with megestrol acetate. However, only 1 patient
in the irosustat group experienced SAEs considered related to
the drug compared with 2 patients in the megestrol acetate
group (who experienced thromboembolic AEs typical of
megestrol acetate treatment). Therefore, irosustat may have a
favorable safety profile in this population of patients with
advanced endometrial cancer. Moreover, the nonoverlapping
adverse-effect profiles of irosustat and megestrol acetate offer
the potential for a regimen combining these 2 drugs.
Given the poor response rates of women with advanced
endometrial cancer and the need for more potent treatments,
combination with progestogens should be investigated. Fur-
ther studies should explore combining STS inhibitors with
other hormonal agents such as aromatase inhibitors, which
may provide some additional benefit for patients with ER-
positive tumors. This is being investigated in an ongoing
clinical trial in patients with breast cancer (ClinicalTrials.gov;
NCT01785992).
As with studies of this design, some methodological
issues may have affected the interpretation of data from this
study. Given ethical considerations in cancer trials, a placebo
was not used in this study; however, use of a placebomay have
enabled establishment of a background response rate in this
population of patients with ER-positive, advanced/recurrent
endometrial cancer. Other aspects of study design may have
masked the true treatment effect of irosustat versus megestrol
acetate. Specifically, tumors within the enrolled study pop-
ulation varied with respect to PR expression and thus po-
tentially contributed to variability in response. In addition, the
study design did not incorporate serial quantification of
hormone receptor positivity during treatment to ascertain
whether loss of expression contributed to response status.
In conclusion, the results of this study suggest that
hormonal therapy has a different safety profile to chemo-
therapy for ER-positive endometrial cancer, with approxi-
mately one third of patients experiencing long-term disease
TABLE 3. Summary of TRAEs occurring in more than 1 patient by treatment group (safety population)*
Irosustat 40 mg (N = 36) n (%)
Megestrol Acetate 160 mg
(N = 35) n (%)
Total Mild/Moderate† Severe† Total Mild/Moderate† Severe†
Patients experiencing any TRAEs 20 (55.6) 17 (47.2) 3 (8.3) 13 (37.1) 10 (28.6) 3 (8.6)
Dry skin 14 (38.9) 13 (36.1) 1 (2.8) 3 (8.6) 3 (8.6) 0
Asthenia 4 (11.1) 3 (8.3) 1 (2.8) 2 (5.7) 1 (2.9) 0
Fatigue 3 (8.3) 3 (8.3) 0 1 (2.9) 1 (2.9) 0
Constipation 3 (8.3)‡ 2 (5.6) 0 0 0 0
Nausea 2 (5.6) 2 (5.6) 0 1 (2.9) 1 (2.9) 0
Vomiting 2 (5.6) 2 (5.6) 0 0 0 0
Muscle spasms 2 (5.6) 2 (5.6) 0 0 0 0
Headache 2 (5.6) 2 (5.6) 0 0 0 0
Hyponatremia 1 (2.8) 0 1 (2.8) 0 0 0
Hypertension 1 (2.8) 0 1 (2.8) 0 0 0
Hot flush 0 0 0 2 (5.7) 2 (5.7) 0
Dyspnea 0 0 0 2 (5.7) 2 (5.7) 0
Pulmonary embolism 0 0 0 2 (5.7) 0 2 (5.7)
Hyperglycemia 0 0 0 1 (2.9) 0 1 (2.9)
*All severe TRAEs reported.
†Mild/moderate defined as grade 1 or 2, severe defined as grade 3 or higher.
‡Severity of 1 result missing.
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control. The results also suggest that the use of irosustat as a
monotherapy is not efficacious enough and should be in-
vestigated in combination with other hormonal or targeted
agents. Classical hormonal therapy with progesterone agents
is still considered the standard treatment for postmenopausal
women with hormone receptor-positive endometrial carci-
noma. It is possible that the association of different pathways
of hormonal therapies may increase the efficacy of different
hormonal agents in endometrial cancer.
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